Cognition Therapeutics Statistics
Want to see CGTX full AI Analyst Report?
Cognition Therapeutics (CGTX) Stock Statistics & Valuation Metrics
Total Valuation
Cognition Therapeutics has a market cap or net worth of $63.74M. The enterprise value is $60.31M.
- Market Cap
- $63.74M
- Enterprise Value
- $60.31M
Share Statistics
Cognition Therapeutics has 95,100,820 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 95,100,820
- Owned by Insiders
- 10.17%
- Owned by Institutions
- 13.47%
Financial Efficiency
Cognition Therapeutics’s return on equity (ROE) is -0.69 and return on invested capital (ROIC) is -136.92%.
- Return on Equity (ROE)
- -0.69
- Return on Assets (ROA)
- -0.49
- Return on Invested Capital (ROIC)
- -136.92%
- Return on Capital Employed (ROCE)
- -1.39
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.68M
- Employee Count
- 14
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Cognition Therapeutics is -3.97. Cognition Therapeutics’s PEG ratio is -0.03.
- PE Ratio
- -3.97
- PS Ratio
- 0.00
- PB Ratio
- 2.18
- Price to FCF
- -4.17
- Price to Operating Cash Flow
- -4.17
- PEG Ratio
- -0.03
Income Statement
In the last 12 months, Cognition Therapeutics had revenue of 0 and earned -23.49M in profits. Earnings per share was -0.32.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -47.80M
- Pretax Income
- -23.49M
- Net Income
- -23.49M
- EBITDA
- -23.25M
- Earnings Per Share (EPS)
- -0.32
Cash Flow
In the last 12 months, operating cash flow was -15.29M and capital expenditures 0, giving a free cash flow of -15.29M billion.
- Operating Cash Flow
- -15.29M
- Free Cash Flow
- -15.29M
- Free Cash Flow per Share
- -0.16
Dividends & Yields
Cognition Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -23.36%
- Earnings Yield
- -24.43%
Stock Price Statistics
- Beta
- 2.31
- 52-Week Price Change
- -60.12%
- 50-Day Moving Average
- 0.88
- 200-Day Moving Average
- 1.04
- Relative Strength Index (RSI)
- 37.99
- Average Volume (3m)
- 478.57K
Important Dates
Cognition Therapeutics upcoming earnings date is Mar 31, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Mar 31, 2027
- Ex-Dividend Date
- ―
Financial Position
Cognition Therapeutics as a current ratio of 3.45, with Debt / Equity ratio of 1.86%
- Current Ratio
- 3.45
- Quick Ratio
- 3.45
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.56
- Interest Coverage Ratio
- -3676.85
Taxes
In the past 12 months, Cognition Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Cognition Therapeutics EV to EBITDA ratio is -2.23, with an EV/FCF ratio of -2.30.
- EV to Sales
- 0.00
- EV to EBITDA
- -2.23
- EV to Free Cash Flow
- -2.30
- EV to Operating Cash Flow
- -2.30
Balance Sheet
Cognition Therapeutics has $30.76M in cash and marketable securities with $489.00K in debt, giving a net cash position of $30.27M billion.
- Cash & Marketable Securities
- $30.76M
- Total Debt
- $489.00K
- Net Cash
- $30.27M
- Net Cash Per Share
- $0.32
- Tangible Book Value Per Share
- $0.31
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Cognition Therapeutics is $3.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $3.00
- Price Target Upside
- 347.76% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 2
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 62.99%
Scores
- Smart Score
- 6
- AI Score
- 47
